Factsheet: ALPINE - Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

 PDF   4   08/2021

ALPINE in an ongoing, head-to-head phase 3, randomized, openlabel study comparing zanubrutinib versus ibrutinib treatment in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL).

In an interim analysis zanubrutinib was shown to have a superior response rate and a lower rate of atrial fibrillation/flutter as compared with ibrutinib.

Rating

Rate this resource